IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals
IDEXX Laboratories (Nasdaq: IDXX), a leading pet healthcare innovator, has released its 2024 Corporate Responsibility Report highlighting significant achievements across three key pillars. The company launched groundbreaking innovations including the IDEXX inVue Dx� Cellular Analyzer and IDEXX Cancer Dx� testing for early cancer detection in pets.
Notable accomplishments include supporting over 79,000 animals in underserved communities, providing $5.5 million in continuing education credits, and achieving an 80% employee engagement rate. Environmental initiatives featured signing three virtual power purchase agreements and maintaining a 35% electric and hybrid commercial fleet. The company serviced over 34,000 instruments and completed 90,000 point-of-service upgrades to advance product circularity.
IDEXX Laboratories (Nasdaq: IDXX), innovatore leader nel settore della salute degli animali domestici, ha pubblicato il suo Rapporto sulla Responsabilità Aziendale 2024, evidenziando importanti risultati in tre pilastri fondamentali. L'azienda ha lanciato innovazioni rivoluzionarie come l'IDEXX inVue Dx� Cellular Analyzer e i test IDEXX Cancer Dx� per la diagnosi precoce del cancro negli animali domestici.
Tra i traguardi più rilevanti si segnalano il supporto a oltre 79.000 animali in comunità svantaggiate, l'erogazione di 5,5 milioni di dollari in crediti per l'educazione continua e il raggiungimento di un tasso di coinvolgimento dei dipendenti dell'80%. Le iniziative ambientali hanno incluso la firma di tre accordi virtuali per l'acquisto di energia e il mantenimento di una flotta commerciale con il 35% di veicoli elettrici e ibridi. L'azienda ha inoltre assistito oltre 34.000 strumenti e completato 90.000 aggiornamenti point-of-service per migliorare la circolarità dei prodotti.
IDEXX Laboratories (Nasdaq: IDXX), un innovador lÃder en el cuidado de la salud de mascotas, ha publicado su Informe de Responsabilidad Corporativa 2024 destacando logros significativos en tres pilares clave. La compañÃa lanzó innovaciones revolucionarias como el IDEXX inVue Dxâ„� Cellular Analyzer y las pruebas IDEXX Cancer Dxâ„� para la detección temprana del cáncer en mascotas.
Entre los logros más destacados se encuentran el apoyo a más de 79,000 animales en comunidades desfavorecidas, la provisión de 5.5 millones de dólares en créditos para educación continua y alcanzar una tasa de compromiso de empleados del 80%. Las iniciativas ambientales incluyeron la firma de tres acuerdos virtuales de compra de energÃa y mantener una flota comercial con un 35% de vehÃculos eléctricos e hÃbridos. La empresa también dio servicio a más de 34,000 instrumentos y completó 90,000 actualizaciones en el punto de servicio para avanzar en la circularidad del producto.
IDEXX Laboratories (나스ë‹�: IDXX)ëŠ� ë°˜ë ¤ë™ë¬¼ ê±´ê°• ê´€ë¦� í˜ì‹ ì� ì„ ë„하는 기업으로ì„� 2024ë…� 기업 사회 ì±…ìž„ ë³´ê³ ì„œë¥¼ 발표하며 ì„� 가지 주요 분야ì—서 중요í•� 성과ë¥� 강조했습니다. 회사ëŠ� ë°˜ë ¤ë™ë¬¼ ì•� 조기 진단ì� 위한 IDEXX inVue Dxâ„� ì„¸í¬ ë¶„ì„ê¸�ì™¶Ä IDEXX Cancer Dxâ„� ê²€ì‚� ë“� íšê¸°ì ì¸ í˜ì‹ ì œí’ˆì� 출시했습니다.
주요 성과로는 소외ë� ì§€ì—사회ì—ì„� 79,000마리 ì´ìƒì� ë™ë¬¼ì� ì§€ì›í•˜ê³�, 550ë§� 달러 ìƒë‹¹ì� ì§€ì†� êµìœ¡ í¬ë ˆë”§ì„ ì œê³µí–ˆìœ¼ë©�, 80%ì� ì§ì› 참여ìœ�ì� 달성í•� ì ì´ ìžˆìŠµë‹ˆë‹¤. 환경 ì´ë‹ˆì…”티브로ëŠ� ì„� ê±´ì˜ ê°€ìƒ� ì „ë ¥ 구매 계약 ì²´ê²°ê³� 35% ì „ê¸° ë°� 하ì´ë¸Œë¦¬ë“� ìƒì—…ìš� 차량 ìœ ì§€ê°€ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹�. ë˜í•œ 회사ëŠ� 34,000대 ì´ìƒì� 기기ë¥� 서비스하ê³� 90,000ê±´ì˜ í˜„ìž¥ 서비ìŠ� ì—…ê·¸ë ˆì´ë“�ë¥� 완료하여 ì œí’ˆ ìˆœí™˜ì„±ì„ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹�.
IDEXX Laboratories (Nasdaq : IDXX), un innovateur de premier plan dans le domaine des soins de santé pour animaux de compagnie, a publié son Rapport sur la Responsabilité d'Entreprise 2024 mettant en lumière des réalisations significatives dans trois piliers clés. L'entreprise a lancé des innovations révolutionnaires telles que l'IDEXX inVue Dx� Cellular Analyzer et les tests IDEXX Cancer Dx� pour la détection précoce du cancer chez les animaux de compagnie.
Parmi les accomplissements notables figurent le soutien à plus de 79 000 animaux dans des communautés défavorisées, la fourniture de 5,5 millions de dollars en crédits de formation continue, et l'atteinte d'un taux d'engagement des employés de 80%. Les initiatives environnementales ont inclus la signature de trois accords d'achat d'électricité virtuelle et le maintien d'une flotte commerciale composée à 35 % de véhicules électriques et hybrides. L'entreprise a également assuré la maintenance de plus de 34 000 instruments et réalisé 90 000 mises à jour sur site afin de promouvoir la circularité des produits.
IDEXX Laboratories (Nasdaq: IDXX), ein führender Innovator im Bereich der Tiergesundheit, hat seinen Corporate Responsibility Report 2024 veröffentlicht, der bedeutende Erfolge in drei zentralen Säulen hervorhebt. Das Unternehmen brachte bahnbrechende Innovationen wie den IDEXX inVue Dx� Cellular Analyzer und die IDEXX Cancer Dx� Tests zur frühzeitigen Krebsdiagnose bei Haustieren auf den Markt.
Zu den bemerkenswerten Erfolgen zählen die Unterstützung von über 79.000 Tieren in benachteiligten Gemeinden, die Bereitstellung von 5,5 Millionen US-Dollar an Fortbildungsguthaben sowie eine 80%ige Mitarbeiterbindungsrate. Umweltinitiativen umfassten den Abschluss von drei virtuellen Stromkaufverträgen und die Aufrechterhaltung eines 35%igen Anteils an Elektro- und Hybridfahrzeugen in der gewerblichen Flotte. Das Unternehmen betreute zudem über 34.000 Geräte und führte 90.000 Point-of-Service-Upgrades durch, um die Produktzirkularität zu fördern.
- None.
- None.
The Care We Advance
IDEXX brings clarity to the complex world of veterinary medicine through innovative diagnostic and software solutions. Key highlights from the report include the following:
- Significantly advanced our innovation strategy in 2024, supporting the launch of the IDEXX inVue Dx� Cellular Analyzer, a groundbreaking slide-free, real-time cellular imaging platform, and exited 2024 with eight additional new products and services launched or ready to launch.
- Revolutionized cancer care by launching IDEXX Cancer Dx� testing in
North America in March 2025, a first-of-its-kind diagnostic panel, addressing a critical need for early cancer detection, starting with canine lymphoma, and planning to expand IDEXX Cancer Dx testing over the next three years to cover the majority of canine cancer cases. - Supported underserved communities by enabling access to care for over 79,000 animals in 2024, with a cumulative total of over 704,000 animals through our global social initiatives since 2022.
- Provided the equivalent of approximatelyÂ
in continuing education credit offerings to veterinary professionals in 2024.$5.5 million
The People We Support
IDEXX strives to create a collaborative and inclusive culture that embraces everyone's unique perspectives, talents, and experiences. Key highlights from the report include the following:
- Logged over 86,000 hours of learning and development, including 23,200 hours of STEM and AI learning.
- Supported achieving over 25,000 self-reported employee volunteer hours, exceeding our 2025 goal of 15,000 annual volunteer hours.
- Achieved a favorable engagement rate of
80% on our annual employee engagement survey.
The Planet We Share
IDEXX recognizes the importance of protecting the planet and its relationship to animal and human health. Key highlights from the report include the following:
- Signed three virtual power purchase agreements to add new, clean electricity to the North American and European energy grids.
- Added more electric and hybrid vehicles to our commercial fleet, which is composed of over
35% electric and hybrid models. - Advanced global product circularity in 2024 by servicing over 34,000 instruments and completing over 90,000 point-of-service upgrades on select IDEXX instruments.
"We made steady progress in 2024, advancing our corporate responsibility goals and fulfilling our commitments across our pillars—The Care We Advance, The People We Support, and The Planet We Share," said Jay Mazelsky, IDEXX President and Chief Executive Officer. "I remain proud of how IDEXX amplifies our Purpose through our corporate responsibility initiatives, which all support and are aligned with our long-term business strategy."
IDEXX's 2024 report covers corporate responsibility topics that we believe are most relevant to our Purpose and stakeholders. We use well-established reporting standards that are aligned with frameworks, such as those released by the Sustainability Accounting Standards Board and the Task Force on Climate-Related Disclosures. Read the 2024 Corporate Responsibility Report .
About IDEXX
IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to
View original content to download multimedia:
SOURCE IDEXX Laboratories, Inc.